Analyst consensus rating
Faeth Therapeutics Analyst Rating: Strong Buy
Direct answer
Faeth Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $56.67.
Forecast evidence checked September 28, 2026.
Get free Faeth Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $27.77
- Average price target
- $56.67
- High price target
- $70.00
- Low price target
- $46.00
- Low target gap
- +65.6%
- Target upside
- +104.1%
- High target gap
- +152.1%
- Target range width
- 86.4%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- September 28, 2026
- Valid through
- October 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Faeth Therapeutics?
Faeth Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $56.67.
How far are Faeth Therapeutics's low and high targets from the recorded price?
The low target implies +65.6%, while the high target implies +152.1%.
How many analysts are included in Faeth Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Faeth Therapeutics's target upside or downside calculated?
The average target of $56.67 is divided by the recorded price of $27.77, then one is subtracted to produce +104.1%. This does not guarantee a future return.
When was Faeth Therapeutics's analyst forecast verified?
The data was verified on 2026-09-28. The dataset is valid through 2026-10-05.